Abstract 191
Vascular targeted photodynamic therapy (VTP) is based on in-situ photosensitization of a circulating drug leading to intravascular reactive oxygen species (ROS) generation and the subsequent tumors’ blood vessel occlusion that lead to the tumor necrosis. We have developed a series of bacteriochlorophyll derivatives, among them WST11 (TOOKAD®-Soluble) a water-soluble agent that has just been granted approval by the European community (EMA) for the treatment of early/intermediate prostate cancer. Application to other cancers, specifically to pancreatic ductal adenocarcinoma (PDAC) is being evaluated and may require adjustments of the treatment conditions. The following work presents the first pre-clinical results using WST11-VTP to treat syngeneic PDAC in mice.